Anwen Liu

2.1k total citations
58 papers, 575 citations indexed

About

Anwen Liu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anwen Liu has authored 58 papers receiving a total of 575 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Anwen Liu's work include Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (14 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Anwen Liu is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (14 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Anwen Liu collaborates with scholars based in China, United States and Switzerland. Anwen Liu's co-authors include Zhimin Zeng, Jing Cai, Long Huang, Xiaoli Zeng, Xia Wang, Peng Xu, Yunwei Liu, Yuxi Luo, Yanxin Chen and Yanxin Chen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Anwen Liu

55 papers receiving 566 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anwen Liu China 13 288 236 151 82 71 58 575
Christian Dierkes Germany 12 165 0.6× 142 0.6× 150 1.0× 101 1.2× 76 1.1× 24 569
Gaël S. Roth France 14 157 0.5× 98 0.4× 205 1.4× 76 0.9× 80 1.1× 46 524
Kenneth B. Fallon United States 12 150 0.5× 85 0.4× 159 1.1× 87 1.1× 54 0.8× 19 504
Dawei Yang China 9 274 1.0× 150 0.6× 284 1.9× 117 1.4× 76 1.1× 16 626
Eleonora Lai Italy 14 315 1.1× 145 0.6× 205 1.4× 154 1.9× 45 0.6× 46 572
Alexander Meisel Switzerland 12 183 0.6× 102 0.4× 147 1.0× 88 1.1× 51 0.7× 27 486
Xiaodong Su China 16 207 0.7× 288 1.2× 311 2.1× 212 2.6× 105 1.5× 38 752
Didem Taştekin Türkiye 15 197 0.7× 87 0.4× 185 1.2× 115 1.4× 72 1.0× 66 507

Countries citing papers authored by Anwen Liu

Since Specialization
Citations

This map shows the geographic impact of Anwen Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anwen Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anwen Liu more than expected).

Fields of papers citing papers by Anwen Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anwen Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anwen Liu. The network helps show where Anwen Liu may publish in the future.

Co-authorship network of co-authors of Anwen Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Anwen Liu. A scholar is included among the top collaborators of Anwen Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anwen Liu. Anwen Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Xu, Wenjie, Hao Yu, Yuxi Luo, et al.. (2025). Integrated multi-omics reveals glycolytic gene signatures of lung adenocarcinoma brain metastasis and the impact of Rac2 lactylation on immunosuppressive microenvironment. Journal of Translational Medicine. 23(1). 1193–1193. 1 indexed citations
3.
Chen, Yanxin, Yuxi Luo, Yunwei Liu, Daya Luo, & Anwen Liu. (2025). Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study. Cancer Immunology Immunotherapy. 74(2). 52–52. 3 indexed citations
4.
Ai, Xinghao, Yunyan Zhang, Tongmei Zhang, et al.. (2025). A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer.. Journal of Clinical Oncology. 43(16_suppl). 8007–8007. 2 indexed citations
5.
Yu, Yongfeng, Yan Yu, Yan Zhang, et al.. (2024). Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib/II, open-label study.. Journal of Clinical Oncology. 42(16_suppl). 8089–8089. 3 indexed citations
6.
7.
8.
Luo, Yuxi, et al.. (2023). Patients harboring uncommon EGFR exon 19delins variants of advanced non-small-cell lung cancer and response to osimertinib: A multi-center retrospective study.. Journal of Clinical Oncology. 41(16_suppl). e21184–e21184. 1 indexed citations
9.
10.
Xu, Peng, et al.. (2023). Oncostatin M/Oncostatin M Receptor Signal Induces Radiation-Induced Heart Fibrosis by Regulating SMAD4 in Fibroblast. International Journal of Radiation Oncology*Biology*Physics. 118(1). 203–217. 8 indexed citations
11.
Hu, Jialing, et al.. (2022). Risk Analysis of Severe Thrombocytopenia in Nasopharyngeal Carcinoma During Concurrent Radio-Chemotherapy. Frontiers in Oncology. 11. 754624–754624. 2 indexed citations
12.
13.
14.
15.
Ai, Xinghao, Jiuwei Cui, Jiexia Zhang, et al.. (2020). Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641). Clinical Cancer Research. 27(3). 704–712. 31 indexed citations
16.
17.
Zeng, Zhimin, Xiaoli Zeng, Peng Zhang, et al.. (2020). BRCA1 protects cardiac microvascular endothelial cells against irradiation by regulating p21-mediated cell cycle arrest. Life Sciences. 244. 117342–117342. 20 indexed citations
18.
Huang, Long, Jiancheng Li, Ruiru Wang, et al.. (2020). Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy options. Molecular Medicine. 26(1). 88–88. 12 indexed citations
19.
Zeng, Xiaoli, et al.. (2017). Optimal treatment and prognostic factors for esthesioneuroblastoma: retrospective analysis of 187 Chinese patients. BMC Cancer. 17(1). 254–254. 23 indexed citations
20.
Yang, Xiaokang, Yi Xu, Rui Zhang, et al.. (2009). Shanghai Jiao Tong University participation in high-level feature extraction and surveillance event detection at TRECVID 2009. TRECVID. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christian Dierkes Breakdown of academic impact, for papers by Gaël S. Roth Breakdown of academic impact, for papers by Kenneth B. Fallon Breakdown of academic impact, for papers by Dawei Yang Breakdown of academic impact, for papers by Eleonora Lai Breakdown of academic impact, for papers by Alexander Meisel Breakdown of academic impact, for papers by Xiaodong Su Breakdown of academic impact, for papers by Didem Taştekin
Rankless by CCL
2026